GlobeNewswire: Adhera Therapeutics, Inc. Contains the last 10 of 32 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:50:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/01/25/2595237/0/en/Adhera-Therapeutics-to-Collaborate-with-Alberta-Diabetes-Institute-University-of-Alberta-to-Initiate-Clinical-Trial-of-MLR-1023-in-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes2023-01-25T14:00:00Z<![CDATA[Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (“ADI”) at the University of Alberta (“U of A”), located in Edmonton, Alberta, Canada.]]>https://www.globenewswire.com/news-release/2022/09/19/2518415/0/en/Adhera-Therapeutics-Announces-CEO-Senior-Management-Changes-Plans-for-NASDAQ-Uplist.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist2022-09-19T13:15:00Z<![CDATA[Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed Subhan PhD MBA JD as Chief Executive Officer of Adhera Therapeutics, effective September 30, 2022. The same day, Dr. Subhan was elected to serve as Chairman of the Board.]]>https://www.globenewswire.com/news-release/2022/07/19/2481940/0/en/Adhera-Therapeutics-Signs-Letter-of-Intent-to-Acquire-CD71-Targeted-Cancer-Therapy-Paclitaxel-Gallium-Transferrin.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin2022-07-19T13:15:00Z<![CDATA[Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (“PGT”), a novel protein complex for targeted treatment of advanced cancers.]]>https://www.globenewswire.com/news-release/2022/05/19/2447045/0/en/Adhera-Therapeutics-Appoints-Trond-K-Waerness-as-Chairman-of-the-Board-Company-Focuses-on-Uplist-to-NASDAQ.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ2022-05-19T13:15:00Z<![CDATA[Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021.]]>https://www.globenewswire.com/news-release/2022/03/21/2406798/0/en/Adhera-Therapeutics-Names-Preeminent-Diabetes-Pioneer-Dr-Jean-Buteau-to-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board2022-03-21T13:37:00Z<![CDATA[Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board. Dr. Buteau, a published scientist, and award-winning pioneer in the field of diabetes, will lend his expertise and oversight to help advance Adhera’s pipeline, including MLR-1023, the Company’s Phase 2-ready drug candidate as a novel therapeutic for treating Type 1 diabetes (T1D).]]>https://www.globenewswire.com/news-release/2022/01/20/2370195/0/en/Adhera-Therapeutics-Announces-Uplisting-to-OTCQB-Venture-Marketplace.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace2022-01-20T13:45:00Z<![CDATA[Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”). Adhera will commence trading on the OTCQB at the market open on January 20, 2022 under the ticker “ATRX.” The Company believes that the uplist will create greater visibility to retail and institutional investors, as well as further enhance trading liquidity.]]>https://www.globenewswire.com/news-release/2021/11/22/2339159/0/en/Adhera-Therapeutics-Receives-Notice-of-Allowance-for-New-Canadian-Patent-Covering-MLR-1019-for-Dyskinesia-and-Related-Disorders.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders2021-11-22T15:00:00Z<![CDATA[Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Canadian patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company from Melior Discovery (“Melior”) company Melior Pharmaceuticals II, LLC (“Melior 2”). Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, “Methods of Treating Dyskinesia and Related Disorders.”]]>https://www.globenewswire.com/news-release/2021/11/08/2329414/0/en/Adhera-Therapeutics-Announces-Appointment-of-Dr-Zahed-Subhan-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors2021-11-08T14:15:00Z<![CDATA[Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Company’s Board of Directors.]]>https://www.globenewswire.com/news-release/2021/10/20/2317559/0/en/Adhera-Therapeutics-Expands-Relationship-with-Melior-Pharmaceuticals-I-Adds-NASH-and-Pulmonary-Inflammation-to-Portfolio-of-Target-Indications.html?f=22&fvtc=4&fvtv=39343Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications2021-10-20T13:35:00Z<![CDATA[Baton Rouge, LA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has extended its relationship with Melior Pharmaceuticals I, Inc. (“Melior Pharma 1”) through the addition of exclusive development rights for two more indications to the existing licensing agreement covering MLR-1023 (tolimidone), one of the world’s only potent and specific lyn kinase activators. As disclosed on August 24, 2021, Adhera executed an exclusive license agreement with Melior Pharma 1 granting Adhera sole rights to develop MLR-1023 as a novel Phase 2-ready therapeutic for Type 1 diabetes.]]>https://www.globenewswire.com/news-release/2021/10/15/2315095/0/en/Manufacturing-Commences-on-Adhera-s-MLR-1019-for-Phase-2a-Clinical-Trial-Treating-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=39343Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease2021-10-15T14:21:50Z<![CDATA[IP Estate Grows with New Korean Patent Issued]]>